Mutations that disrupt the Nrf2-Keap-1 interaction, cause a constitutive activation of this transcription factor, and such mutations are observed in lung, colorectal, and prostate cancers [44–46]. This evidence concerns the gene NFE2L2 and prostate carcinoma.